528 related articles for article (PubMed ID: 33117358)
21. Adenosine in cancer immunotherapy: Taking off on a new plane.
Zhang C; Wang K; Wang H
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189005. PubMed ID: 37913941
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible.
Ohta A; Madasu M; Subramanian M; Kini R; Jones G; Choukèr A; Ohta A; Sitkovsky M
Int Immunol; 2014 Feb; 26(2):83-91. PubMed ID: 24150242
[TBL] [Abstract][Full Text] [Related]
23. Adenosine-A2A Receptor Pathway in Cancer Immunotherapy.
Sun C; Wang B; Hao S
Front Immunol; 2022; 13():837230. PubMed ID: 35386701
[TBL] [Abstract][Full Text] [Related]
24. Small molecule AZD4635 inhibitor of A
Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810
[TBL] [Abstract][Full Text] [Related]
25. Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.
Sek K; Mølck C; Stewart GD; Kats L; Darcy PK; Beavis PA
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513816
[TBL] [Abstract][Full Text] [Related]
26. Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection.
Hatfield SM; Kjaergaard J; Lukashev D; Belikoff B; Schreiber TH; Sethumadhavan S; Abbott R; Philbrook P; Thayer M; Shujia D; Rodig S; Kutok JL; Ren J; Ohta A; Podack ER; Karger B; Jackson EK; Sitkovsky M
J Mol Med (Berl); 2014 Dec; 92(12):1283-92. PubMed ID: 25120128
[TBL] [Abstract][Full Text] [Related]
27. Adenosine A
Yu F; Zhu C; Xie Q; Wang Y
J Med Chem; 2020 Nov; 63(21):12196-12212. PubMed ID: 32667814
[TBL] [Abstract][Full Text] [Related]
28. Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer.
Sitkovsky M; Ohta A
J Mol Med (Berl); 2013 Feb; 91(2):147-55. PubMed ID: 23334369
[TBL] [Abstract][Full Text] [Related]
29. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.
Mediavilla-Varela M; Castro J; Chiappori A; Noyes D; Hernandez DC; Allard B; Stagg J; Antonia SJ
Neoplasia; 2017 Jul; 19(7):530-536. PubMed ID: 28582704
[TBL] [Abstract][Full Text] [Related]
30. Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway.
Choukèr A; Thiel M; Lukashev D; Ward JM; Kaufmann I; Apasov S; Sitkovsky MV; Ohta A
Mol Med; 2008; 14(3-4):116-23. PubMed ID: 18163162
[TBL] [Abstract][Full Text] [Related]
31. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy.
Leone RD; Lo YC; Powell JD
Comput Struct Biotechnol J; 2015; 13():265-72. PubMed ID: 25941561
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches.
Thompson EA; Powell JD
Annu Rev Med; 2021 Jan; 72():331-348. PubMed ID: 32903139
[TBL] [Abstract][Full Text] [Related]
33. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
[TBL] [Abstract][Full Text] [Related]
34. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response.
Sitkovsky MV
Trends Immunol; 2009 Mar; 30(3):102-8. PubMed ID: 19201652
[TBL] [Abstract][Full Text] [Related]
35. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
36. Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.
Bai Y; Zhang X; Zheng J; Liu Z; Yang Z; Zhang X
J Exp Clin Cancer Res; 2022 Oct; 41(1):302. PubMed ID: 36229853
[TBL] [Abstract][Full Text] [Related]
37. Boosting Cancer Immunotherapy via the Convenient A2AR Inhibition Using a Tunable Nanocatalyst with Light-Enhanced Activity.
Yu W; Sun J; Wang X; Yu S; Yan M; Wang F; Liu X
Adv Mater; 2022 Feb; 34(8):e2106967. PubMed ID: 34910838
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models.
Karoon Kiani F; Izadi S; Ansari Dezfouli E; Ebrahimi F; Mohammadi M; Chalajour H; Mortazavi Bulus M; Nasr Esfahani M; Karpisheh V; Mahmoud Salehi Khesht A; Abbaszadeh-Goudarzi K; Soleimani A; Gholizadeh Navashenaq J; Ahmadi M; Hassannia H; Hojjat-Farsangi M; Shahmohammadi Farid S; Hashemi V; Jadidi-Niaragh F
Life Sci; 2022 Jan; 288():120166. PubMed ID: 34813798
[TBL] [Abstract][Full Text] [Related]
39. A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models.
Willingham SB; Ho PY; Hotson A; Hill C; Piccione EC; Hsieh J; Liu L; Buggy JJ; McCaffery I; Miller RA
Cancer Immunol Res; 2018 Oct; 6(10):1136-1149. PubMed ID: 30131376
[TBL] [Abstract][Full Text] [Related]
40. Concomitant blockade of A2AR and CTLA-4 by siRNA-loaded polyethylene glycol-chitosan-alginate nanoparticles synergistically enhances antitumor T-cell responses.
Ghasemi-Chaleshtari M; Kiaie SH; Irandoust M; Karami H; Nabi Afjadi M; Ghani S; Aghaei Vanda N; Ghaderi Sede MJ; Ahmadi A; Masjedi A; Hassannia H; Atyabi F; Hojjat-Farsangi M; Namdar A; Ghalamfarsa G; Jadidi-Niaragh F
J Cell Physiol; 2020 Dec; 235(12):10068-10080. PubMed ID: 32488862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
